The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Klimenko A.A.

Kafedra fakul'tetskoĭ terapii im. akad. A.I. Nesterova lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Demidova N.A.

Kafedra fakul'tetskoĭ terapii im. akad. A.I. Nesterova lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Shostak N.A.

Kafedra fakul'tetskoĭ terapii im. akad. A.I. Nesterova lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Novikov I.V.

Kafedra fakul'tetskoĭ terapii im. akad. A.I. Nesterova lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Diagnostic and prognostic value of the brain natriuretic peptide in patients with pulmonary embolism

Authors:

Klimenko A.A., Demidova N.A., Shostak N.A., Novikov I.V.

More about the authors

Journal: Journal of Venous Disorders. 2011;5(3): 54‑57

Read: 2821 times

Download PDF (RU)
Contact the author
Table of contents

DIAGNOSTIC AND PROGNOSTIC VALUE OF THE BRAIN NATRIURETIC PEPTIDE IN PATIENTS WITH PULMONARY EMBOLISM
DIAGNOSTIC AND PROGNOSTIC VALUE OF THE BRAIN NATRIURETIC PEPTIDE IN PATIENTS WITH PULMONARY EMBOLISM

To cite this article:

Klimenko AA, Demidova NA, Shostak NA, Novikov IV. Diagnostic and prognostic value of the brain natriuretic peptide in patients with pulmonary embolism. Journal of Venous Disorders. 2011;5(3):54‑57. (In Russ.)

Подписка 2026 Флебология (Journal of Venous Disorders)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Outpatient Mana­gement of Venous Thro­mboembolism in Acute Phase. Journal of Venous Diso­rders. 2024;(4):328-338
Fibrin mono­mer in diagnosis of cardiovascular diseases. Russian Cardiology Bulletin. 2024;(4-2):113-120
Asplenia — a new cause of thro­mbosis in pregnant women?. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):71-76
Fatal non-thrombotic pulmonary embo­lism in penis enla­rgement with inje­ctions of hyaluronic acid-based drugs. Fore­nsic Medi­cal Expe­rtise. 2025;(1):59-62
Signs of high embo­lic risk in iliocaval floating thro­mbi. Piro­gov Russian Journal of Surgery. 2025;(3):56-62
Thro­mboembolic complications in the postpartum period. Russian Bulletin of Obstetrician-Gynecologist. 2025;(4):102-107
Ultrasound catheter thro­mbolysis for the treatment of pulmonary embo­lism: the first expe­rience in the Russian Fede­ration. Russian Cardiology Bulletin. 2025;(3):17-24
Abstract:

Predictors of survival in the patients with pulmonary embolism include clinical manifestations of the disease (hypotension, shock), signs of myocardial involvement (troponins), and right ventricle dysfunction. The brain natriuretic peptide synthesized by cariomyocytes in response to the overload of the right-sided heart chambers in patients with pulmonary embolism is one of the markers of dysfunction of the right ventricle. The detection of brain natriuretic peptide in blood makes it possible to estimate the severity of functional dysfunction of the right ventricle and predict the complicated clinical course of pulmonary embolism. The persistence of high blood concentration of this marker in the late period of pulmonary embolism may be regarded as a preclinical sign of chronic postembolic pulmonary hypertension.

Keywords:

pulmonary embolism
chronic postembolic pulmonary hypertension
brain natriuretic peptide
right ventricle dysfunction

Authors:

Klimenko A.A.

Kafedra fakul'tetskoĭ terapii im. akad. A.I. Nesterova lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Demidova N.A.

Kafedra fakul'tetskoĭ terapii im. akad. A.I. Nesterova lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Shostak N.A.

Kafedra fakul'tetskoĭ terapii im. akad. A.I. Nesterova lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Novikov I.V.

Kafedra fakul'tetskoĭ terapii im. akad. A.I. Nesterova lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Close metadata

References:

  1. Kurose M., Yosimura M., Yasue H. Raised plasma BNP in patients with pulmonary thromboembolism. Heart 1997;78:320-321.
  2. Tulevski I.I., Hirsch A., Sanson B.J. et al. Increased brain natriuretic peptide as a marker for right ventricular dysfunction in acute pulmonary embolism. Thromb Haemost 2001;86:1193-1196.
  3. Gutte H., Mortensen J., Jensen C.V. et al. ANP, BNP and D-dimer predict right ventricular dysfunction in patients with acute pulmonary embolism. Clin Physiol Funct Imaging 2010;30:6:466-472.
  4. Torbicki A., Perrier A., Konstantinides S. et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008;29:18:2276-2315.
  5. Grifoni S., Olivotto I., Cecchini P. et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000;101:24:2817-2822.
  6. Goldhaber S.Z., Visani L., De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-1389.
  7. Kasper W., Konstantinides S., Geibel A. et al. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997;77:346-349.
  8. Fremont B., Pacouret G., Jacobi D. et al. Prognostic value of echocardiographic right/left ventricular end-diastolic diameter ratio in patients with acute pulmonary embolism: results from a monocenter registry of 1416 patients. Chest 2008;133:358-362.
  9. Ten Wolde M., Sohne M., Quak E. et al. Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Int Med 2004;164:1685-1689.
  10. Binder L., Pieske B., Olschewski M. et al. N-Terminal Pro-Brain Natriuretic Peptide or Troponin Testing Followed by Echocardiography for Risk Stratification of Acute Pulmonary Embolism. Circulation 2005;112:1573-1579.
  11. Kostrubiec M., Pruszczyk P., Bochowicz A. et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005;26:20:2166-2172.
  12. Konstantinides S., Geibel A., Olschewski M. et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002;106:1263-1268.
  13. Bando M., Ishii Y., Sugiyama Y., Kitamura S. Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Resp Med 1999;93:507-514.
  14. Omland T., Persson A., Ng L. et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913-2918.
  15. Klok F.A., Mos I.C., Huisman M.V. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and metaanalysis. Am J Resp Crit Care Med 2008;178:425-430.
  16. Agterof M.J., Schutgens R.E., Snijder R.J. et al. Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. J Thromb Haemost 2010;8:6:1235-1241.
  17. Wolde M., Tulevski I.I., Mulder J.W. et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003;107:2082-2084.
  18. Kucher N., Printzen G., Doernhoefer T. et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003;107:1576-1578.
  19. Pruszczyk P., Kostrubiec M., Bochowicz A. et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003;22:4:649-653.
  20. Ribeiro A., Lindmarker P., Johnsson H. et al. Pulmonary embolism. One year follow-up with echocardiography doppler and five-year survival analysis. Circulation 1999;99:1325-1330.
  21. Ten Wolde M., Tulevski I.I., Mulder J.W. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003;107:2082-2084.
  22. Jiménez D., Aujesky D., Moores L. et al. Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. Thorax 2011;66:1:75-81.
  23. Silver M.A., Maisel A., Yancy C. et al. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004;10:5:Suppl 3:1-30.
  24. Tulevski I.I., Wolde M.T., van Veldhuisen D.J. et al. Combined utility of brain natriuretic peptide and cardiac troponin T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism. Int J Cardiol 2007;116:161-166.
  25. Dentali F., Donadini M., Gianni M. et al. Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. Int Emerg Med 2009;4:2:123-128.
  26. Reesink H.J., Tulevski I.I., Marcus J.T. et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 2007;84:2:537-543.
  27. Nagaya N., Ando M., Oya H. et al. Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy. Ann Thorac Surg 2002;74:1:180-184.
  28. McDonagh T.A., Robb S.D., Murdoch D.R. et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
  29. Casserly B., Klinger J.R. Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Devel Ther 2009;3:269-287.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.